Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection

NCT04389801 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-05-15

No results posted yet for this study

Summary

To evaluate the efficacy of using Desferal injections for prevention of ARDS in moderate cases with fever , chest tightness and relevant chest images

Conditions

  • Covid 19

Interventions

DRUG

Desferal 500 MG Injection

iron chelating agent

Sponsors & Collaborators

  • Hesham Al-Inany

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-09-30
Completion
2020-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04389801 on ClinicalTrials.gov